Daridorexant
DORA (Dual Orexin Receptor Antagonist), Hypnotic
Daridorexant
Quviviq
Daridorexant (brand name Quviviq) is a dual orexin receptor antagonist (DORA) approved by the FDA in 2022 for adults with insomnia characterized by difficulties with sleep onset and/or sleep maintenance. Unlike benzodiazepines or Z-drugs, it does not enhance GABAergic transmission; instead it blocks the wake-promoting orexin/hypocretin system.
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Classes
DORA (Dual Orexin Receptor Antagonist), Hypnotic
Common uses
Insomnia (sleep onset and maintenance)
Pharmacy
Starting dose
25 mg PO at bedtime; may increase to 50 mg if needed
Preparations
25 mg, 50 mg tablets
US FDA Max
50 mg/d
Pharmacology
Routes
Oral
Onset
~30 min
Duration
~7–8 h
Half-life
~8 h
Bioavailability
~62%
Pregnancy
Limited data; avoid
Legal status
Rx, Schedule IV (US)
Purported mechanism
Selective dual antagonist at OX1R and OX2R orexin receptors; reduces wake drive without GABAergic effects